Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
We explored the prognostic impact of simple indices that reflect the immunological milieu (neutrophils to lymphocyte ratio [NLR] and systemic immune-inflammation [SII]) in 49 platinum-resistant relapsed ovarian cancer patients. The median progression-free survival (PFS) and overall survival (OS) wer...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2024-10-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1749399 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850163301475942400 |
|---|---|
| author | Luxitaa Goenka Nakka Thejeswar Biswajit Dubashi Smita Kayal Prasanth Ganesan |
| author_facet | Luxitaa Goenka Nakka Thejeswar Biswajit Dubashi Smita Kayal Prasanth Ganesan |
| author_sort | Luxitaa Goenka |
| collection | DOAJ |
| description | We explored the prognostic impact of simple indices that reflect the immunological milieu (neutrophils to lymphocyte ratio [NLR] and systemic immune-inflammation [SII]) in 49 platinum-resistant relapsed ovarian cancer patients. The median progression-free survival (PFS) and overall survival (OS) were 4 and 8 months, respectively. Patients with a lower NLR (≤2.89) had a better PFS (5 vs. 2 months [p = 0.02]) and OS (9 vs. 5 months [p = 0.20]). Factors associated with a worse PFS were NLR > 2.8 (hazard ratio [HR] =2.32, p = 0.02) and SII > 639 (HR =3.70, p = 0.002). SII > 639 independently predicted PFS (HR =4.13, p = 0.03). Future studies should study the validity of inflammatory markers and could consider incorporating it as a biomarker in clinical trials. |
| format | Article |
| id | doaj-art-ba39d76a89bc458dbf6a8a2322b90278 |
| institution | OA Journals |
| issn | 0971-5851 0975-2129 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-ba39d76a89bc458dbf6a8a2322b902782025-08-20T02:22:20ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292024-10-01450543043310.1055/s-0042-1749399Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian CancerLuxitaa Goenka0Nakka Thejeswar1https://orcid.org/0000-0001-9282-0564Biswajit Dubashi2https://orcid.org/0000-0001-9852-2525Smita Kayal3Prasanth Ganesan4https://orcid.org/0000-0003-2762-6591Department of Medical Oncology, JIPMER, Puducherry, IndiaDepartment of Medical Oncology, JIPMER, Puducherry, IndiaDepartment of Medical Oncology, JIPMER, Puducherry, IndiaDepartment of Medical Oncology, JIPMER, Puducherry, IndiaDepartment of Medical Oncology, JIPMER, Puducherry, IndiaWe explored the prognostic impact of simple indices that reflect the immunological milieu (neutrophils to lymphocyte ratio [NLR] and systemic immune-inflammation [SII]) in 49 platinum-resistant relapsed ovarian cancer patients. The median progression-free survival (PFS) and overall survival (OS) were 4 and 8 months, respectively. Patients with a lower NLR (≤2.89) had a better PFS (5 vs. 2 months [p = 0.02]) and OS (9 vs. 5 months [p = 0.20]). Factors associated with a worse PFS were NLR > 2.8 (hazard ratio [HR] =2.32, p = 0.02) and SII > 639 (HR =3.70, p = 0.002). SII > 639 independently predicted PFS (HR =4.13, p = 0.03). Future studies should study the validity of inflammatory markers and could consider incorporating it as a biomarker in clinical trials.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1749399platinum-resistant ovarian cancertreatmentoutcomessystemic immune-inflammation indexneutrophil to lymphocyte ratio |
| spellingShingle | Luxitaa Goenka Nakka Thejeswar Biswajit Dubashi Smita Kayal Prasanth Ganesan Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer Indian Journal of Medical and Paediatric Oncology platinum-resistant ovarian cancer treatment outcomes systemic immune-inflammation index neutrophil to lymphocyte ratio |
| title | Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer |
| title_full | Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer |
| title_fullStr | Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer |
| title_full_unstemmed | Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer |
| title_short | Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer |
| title_sort | systemic immune inflammation index predicts outcomes in platinum resistant relapsed ovarian cancer |
| topic | platinum-resistant ovarian cancer treatment outcomes systemic immune-inflammation index neutrophil to lymphocyte ratio |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1749399 |
| work_keys_str_mv | AT luxitaagoenka systemicimmuneinflammationindexpredictsoutcomesinplatinumresistantrelapsedovariancancer AT nakkathejeswar systemicimmuneinflammationindexpredictsoutcomesinplatinumresistantrelapsedovariancancer AT biswajitdubashi systemicimmuneinflammationindexpredictsoutcomesinplatinumresistantrelapsedovariancancer AT smitakayal systemicimmuneinflammationindexpredictsoutcomesinplatinumresistantrelapsedovariancancer AT prasanthganesan systemicimmuneinflammationindexpredictsoutcomesinplatinumresistantrelapsedovariancancer |